Fenfluramine

ALIMENTARY TRACT AND METABOLISM

Also known as: DL-Fenfluramine, fenfluramine HCl, fenfluramine hydrochloride, fintepla, pondimin

OnpEMA approvedFDA approvedPMDA approvedOrphan designationATC A08AA02ATC N03AX26

Data last refreshed: 2026-11-10 (DrugCentral release 2024-11-01)

Open interactive profile (3D, safety, PGx)

Key facts

Fenfluramine is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2020. DrugCentral lists 21 molecular targets, including Slc6a4, ADRA1B and ADRA2C. Recorded indications include Dravet syndrome, Obesity and Seizures associated with Dravet syndrome.

Approval status: onp (first approved 2020 by the FDA).
Molecular targets: Slc6a4, ADRA1B, ADRA2C and ADRA2B (21 listed in DrugCentral).
Indications: Dravet syndrome, Obesity and Seizures associated with Dravet syndrome.
ATC code: A08AA02 (Centrally acting antiobesity products).
Molecular formula: C12H16F3N; molecular weight 231.26 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

Dravet syndrome
Obesity
Seizures associated with Dravet syndrome

Contraindications (6)

Alcoholism
Diabetes mellitus type 1
Diabetes mellitus type 2
Glaucoma
Hypertensive disorder
Pulmonary hypertension

Mechanism & targets

Molecular targets (21)

Target	Gene	Action	Activity
Sodium-dependent serotonin transporter	Slc6a4	unknown	EC50 6.97
Alpha-1B adrenergic receptor	ADRA1B	unknown	Ki 6.85
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.74
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.72
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 6.57
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.43
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 6.40
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 6.20
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 6.18
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 6.17
Muscarinic acetylcholine receptor M1	CHRM1	unknown	Ki 6.02
Beta-1 adrenergic receptor	ADRB1	unknown	Ki 6.00
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 5.84
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 5.79
5-hydroxytryptamine receptor 1B	HTR1B	unknown	Ki 5.74
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 5.73
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 5.49
5-hydroxytryptamine receptor 7	HTR7	unknown	Ki 5.38
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 5.17
Beta-2 adrenergic receptor	ADRB2	unknown	Ki 5.11

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-09-26	PMDA	—	UCB JAPAN CO., LTD.	Yes
2020-12-18	EMA	—	UCB PHARMA S.A.	Yes
2020-06-25	FDA	—	UCB INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
`A08AA02`	ALIMENTARY TRACT AND METABOLISM › ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS › ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS › Centrally acting antiobesity products
`N03AX26`	NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Tricuspid valve incompetence	2007.7
Seizure	1409.6
Mitral valve incompetence	985.2
Pulmonary valve incompetence	836.1
Mitral valve thickening	579.9
Aortic valve incompetence	520.0
Epilepsy	445.9
Off label use	403.3
Prescribed underdose	361.9
Aortic valve thickening	314.2
Petit mal epilepsy	313.5
Generalised tonic-clonic seizure	307.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Fenfluramine is on its molecule page.

Molecular formula	C₁₂H₁₆F₃N
Molecular weight	231.26 g/mol
CAS number	458-24-2
InChIKey	DBGIVFWFUFKIQN-UHFFFAOYSA-N
PubChem CID	3337

CCNC(C)CC1=CC(=CC=C1)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fenfluramine used for?

DrugCentral lists the following indications for Fenfluramine: Dravet syndrome, Obesity and Seizures associated with Dravet syndrome.

How does Fenfluramine work?

Its molecular targets in DrugCentral include Slc6a4, ADRA1B, ADRA2C and ADRA2B.

When was Fenfluramine first approved?

Fenfluramine was first approved by the FDA in 2020.

What is the chemical formula of Fenfluramine?

Fenfluramine has the molecular formula C12H16F3N and a molecular weight of 231.26 g/mol.

Browse: all drugs starting with F · drug guides by category · protein targets A–Z.

Sources

DrugCentral drug card 1150 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
ChEMBL CHEMBL2106217 — compound record and bioactivity
PubChem CID 3337 — chemical identifiers
DrugBank DB00574 — drug record
FDA UNII 2DS058H2CF — substance identity
DailyMed: FDA labels for Fenfluramine — current prescribing information (label search)
UniProt P35368 (ADRA1B) — target protein
UniProt P18825 (ADRA2C) — target protein
UniProt P18089 (ADRA2B) — target protein
UniProt P35348 (ADRA1A) — target protein
UniProt P08913 (ADRA2A) — target protein
UniProt P41595 (HTR2B) — target protein
FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.